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Background: Cardiovascular diseases (CVD) remain the leading cause of mortality and 
morbidity globally. Iron has been suggested to have role in CVD though, epidemiological 
findings have been conflicting. The primary aim of this study was to investigate the possible 
role of body iron in carotid atherosclerosis in a population-based survey. Further, we wanted to 
analyze the prevalence of carotid plaques and differences in gender and age.  
Material and methods: We performed a cross-sectional study based on data from the fifth 
survey of the Tromsø Study conducted in 2001-2002. Atherosclerosis was measured by 
ultrasound examination of the carotid artery in a total of 5423 subjects aged between 32 to 89 
years. Iron status was obtained through laboratory measurements of hemoglobin, s-ferritin, s-
transferrin, transferrin saturation, s-iron and s-TIBC.   
Results: Iron stores and hemoglobin were negatively associated with carotid plaque. The third 
and the fourth quartiles of s-ferritin showed reduced odds by 54.6 % (OR=0.454, 95% CI=0.272 
to 0.758) and by 52.9% (OR=0.471, 95% CI=0.286 to 0.774) respectively, compared with the 
lowest ferritin quartile towards high plaque load in women. Likewise, hemoglobin had a 
protective effect in plaque presence and in high plaque load in women, being reduced by 11.3% 
odds (OR=0.887, 95% CI=0.802 to 0.980) and by 18.3% odds (OR=0.817, 95% CI=0.674 to 
0.989) respectively, per 1 unit increase in hemoglobin compared to men.   
Conclusion: High levels of iron seem to be protective of plaque presence, high plaque load and 
plaque area with consistent findings in women, suggesting that they were associated with lower 
risk of disease.    
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1 Introduction 
The importance of body iron in the development of cardiovascular diseases (CVD) has been 
discussed in the scientific field during the last decades. However, the association between body 
iron status and atherosclerosis has not been extensively investigated, remaining a controversial 
topic with conflicting epidemiological findings. Beyond that, research in the topic has not been 
conducted in a population-based survey in Norway. The study of carotid atherosclerosis 
provides an important tool for the comprehensive of cardiovascular events particularly ischemic 
cerebrovascular events, due to atherosclerotic plaques and stenosis located in carotid 
bifurcation are considered to be major risk factors to stroke (1),(2),(3). 
 
1.1 Atherosclerosis 
The burden of noncommunicable diseases (NCD) caused an estimated 52% of total deaths 
under age 70 globally in 2012 (4). The CVD remain the major cause of mortality worldwide 
causing 17.5 million deaths in 2012. According with the same report, coronary heart disease 
(CHD) is the main cause of mortality leading to 7.4 million deaths, and stroke is the second 
major cause with an estimated 6.7 million deaths in 2012. Atherosclerosis is a chronic disease 
and the major cause of CVD events as ischemic stroke, myocardial infarction and peripheral 
arterial disease (5). It is characterized by the accumulation of cholesterol deposits and cell 
infiltration in the artery wall that compromises the lumen of the vessel, affecting the blood 
circulation and oxygen supply to the heart and the brain. 
Cholesterol or lipid is a fat-like substance that is present in the blood circulation in different 
particles composed by both lipid and proteins, which are referred as lipoproteins (6). They 
include low density lipoproteins (LDL), high density lipoproteins (HDL) and very low density 
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lipoproteins (VLDL). The total serum cholesterol contains about 60% to 70% of LDL 
cholesterol and 20% to 30% of HDL cholesterol.   
The arterial wall is divided in three cylindrical layers with different vascular cell types that are 
separated by macromolecules called elastin lamellae (7), (8). The innermost layer of the artery 
wall is tunica intima and is formed by endothelial cells, acting as an active barrier between the 
vessel wall and the blood circulation. The tunica media is the middle layer formed by smooth 
muscle cells within the extracellular matrix and provides the elastic function of the vessel. The 
outermost layer is the tunica adventitia that contains fibroblasts and the blood vessels that 
nourishes the cells of the arterial vessel. The medial layer is separated from the intima and the 
adventitia by elastin membranes. The figure 1 shows the structure of the arterial vessel wall (9). 
 
Figure 1 Cross-section of the artery wall. 
 
 
1.1.1 Pathogenesis of atherosclerosis 
The pathological process of atherosclerosis may start in childhood (10) and the occurrence of 
the first cardiovascular event usually can last decades (11). The formation of atherosclerotic 
plaque tends to occur in sites with disturbed laminar flow as bifurcations and branchings of 
carotid and coronary arteries, that exhibit characteristics of lower flow velocity and wall shear 
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stress (12). The process of atherosclerosis development is called atherogenesis and it involves 
a cascade of events with different biological processes (13). The main hypothesis of the 
atherogenesis is known as “the response to injury” and it was postulated by Ross in the early 
90’s (14). Multiple factors contribute to this complex and systemic disorder and they include 
endothelial and smooth muscle cells dysfunction, oxidative modifications and inflammatory 
response with intervention of immune cells due to injury of endothelial cells (15). 
The known pathological stages of atherosclerosis can be classified as: 1. Intima-media 
thickening; 2. fatty streaks; 3. intermediate lesions; 4. fibrous plaques; 5. complicated plaques 
(13). The early development of atherosclerosis is characterized by the thickening of the 
subendothelial space that involves lipid deposition and cell infiltration, with later changes in 
the media layer (8). An increase in the intima-media thickness (IMT) includes both the 
widening of intima and the hypertrophy of media and so, the IMT reflects a hypertrophic 
response (16). Mechanical factors as wall shear stress and tensile stress have been implicated 
in the arterial wall thickness (12). Still in the early atherosclerosis, it occurs the fatty streak 
lesion that is defined as the accumulation of apolipoprotein B, the main protein component of 
LDL cholesterol, and the migration of monocytes and dendritic cells within the intima layer 
(17). In this pathological stage, it occurs the differentiation of the monocytes into macrophages, 
and unregulated scavenger receptors identify the oxidized LDL (13). This leads to the formation 
of foam cells that represents the building blocks of the plaque. The accumulation of foam cells 
leads to an increase of the intima thickness and the macrophages conduct a process of 
phagocytosis, ingesting the modified LDL (17). Fatty streak lesion can be found in adolescents 
and young adults (18) and usually it does not cause symptoms, though they may evolve to 
atherosclerotic plaque or disappear (19). The fatty streak lesion anticipates the intermediate 
lesion which is known as preatheroma, that contains lipid pools and multiple layers of 
macrophages and smooth muscle cells (20). The intermediate lesion can evolve to fibrous 
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plaque which is known as atheroma. This complex and occlusive lesion is composed by 
macrophages, smooth muscle cells, T lymphocytes and calcium deposits (14). The proliferation 
of smooth muscle cells and T cells in the intima layer form a cap over the lipid core and the 
retention of apolipoprotein B is expanded (13). The immune cells signal the activation and 
production of cytokines (19). Cytokines are defined as the mediators involved in the immunity 
and inflammation response, and the growth factors are implicated in cell proliferation (14). 
These two molecules seem to act very closely in the atherosclerosis. A complex process occurs 
in the formation of vulnerable plaque involving cell death of macrophage foam cells and smooth 
cells along with the degradation of the extracellular matrix (11). This leads to a necrotic core 
and thinning of the fibrous cap (17). In advanced fibrous plaques, it may occur fissures of the 
endothelial cells or ruptures causing hemorrhage, aggregation of platelet and thrombus 
formation, and consequently, the occlusion of the arterial lumen and ischemia (14). The 
development of the pathological steps of atherosclerosis is shown in the figure 2 (17). 
 
 
Figure 2 Progression of atherosclerotic plaque. 
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1.1.2 Cardiovascular risk factors 
The CVD risks factors have been widely investigated in the last decades and include age, 
gender, hypertension, cigarette smoking, hypercholesterolemia, diabetes mellitus and obesity 
(5). Age while not modifiable, is an important factor to predict incident CVD (21). Age reflects 
the accumulation of atherosclerosis over time and the increased exposure to risk factors. 
Besides, there are cardiovascular changes with age at structure and function levels of the artery, 
which increases the risk of CVD in the older people (22). The Framingham Heart Study showed 
that advancing age increased the incidence of CHD in men and women (23). According to the 
same study, men had higher rate of CHD than women. Differences in the incidence of CHD 
between genders is well documented (24). Premenopausal women have lower incidence of 
CVD although, the risk increases in postmenopausal women (25), (26). The use of estrogen 
therapy has been implicated in the protective effect of CHD in postmenopausal women (27) 
however, evidence has not revealed this. A randomized control trial did not show the risk 
reduction of disease in women with hormone replacement (28). Hypertension is defined as 
systolic blood pressure ≥140 mmHg or diastolic ≥90 mmHg (29) and increases with advancing 
age (30). It is considered to be highly correlated with stroke mortality (31) and a significant risk 
factor for death from CHD (32). The use of blood pressure lowering drugs have reduced 
substantially cardiovascular events in hypertensive patients (33). Moreover, hypertension 
seems to be related with endothelial dysfunction by oxidative stress that can contribute to the 
formation of atherosclerotic plaque (34). Cigarette smoking is a strong risk factor for 
atherosclerosis. It increases the risk by approximately 50% and doubles the incidence of CHD 
(35). A meta-analysis revealed that cigarette smoking is a strong predictor to CVD mortality 
and cardiovascular events and smoking cessation reduced the excess risk among former 
smokers in a dose-response form (36). Moreover, cigarette smoking leads to increased 
oxidation of LDL cholesterol, inflammation and thrombosis, affecting this way all stages of 
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atherosclerosis (37). Hypercholesterolemia or dyslipidemia refers to increased levels of serum 
cholesterol (6). Elevated LDL cholesterol is a major risk factor to atherosclerosis and in 
contrast, high levels of HDL cholesterol is considered to be a protective factor (38), (39). 
Cholesterol-lowering therapy contributes significantly to the reduction of the risk of death and 
morbidity in patients with CHD with an improvement in survival (40). Diabetes mellitus 
represents a major factor for atherosclerosis (41). A study showed that diabetes mellitus 
increased the risk of all-cause and CVD mortality (42). Another study showed that the incidence 
of ischemic stroke is twice in diabetic patients than non-diabetic people (43). Patients with 
diabetes type 2 may benefit from diabetic therapy in terms of reduction of carotid IMT (44). 
Obesity increases the risk for CVD (45), (46). However, its mechanism remains controversial 
and some risk factors of CVD frequently coexist in obesity (45). The genetic component seems 
to have a role in the development of atherosclerosis, where the occurrence of disease depends 
strongly on the interaction between genetic factors and the environment (13). The Framingham 
Heart Study was the first prospective study to suggest a role of family history to risk of CHD 
(23).  
 
1.1.3 Ultrasonography of the carotid artery 
High resolution B-mode ultrasonography is a non-invasive procedure that allows the detection 
of asymptomatic carotid atherosclerosis, providing measures of atherosclerotic plaques and 
IMT (16). The images obtained from the ultrasound are in high accordance with the true 
structure of the artery wall though, this method can not differentiate between the intima and the 
media layers. The IMT consists of approximately 20% of intima and 80% of media. The plaque 
growth occurs along the arterial wall two times faster than it thickens and so, measurements of 
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the IMT are considered to be relatively insensitive (47), while measurements of plaque volume 
and plaque area are considered to be more sensitive measures of atherosclerosis (48). 
 
1.2 Iron hypothesis 
Iron has been suggested to have role in CVD. A possible link between iron stores and risk of 
heart disease was firstly introduced by Sullivan in 1981, who claimed the “iron hypothesis” 
(49). There are gender differences in heart disease incidence where premenopausal women have 
lower incidence compared with men and postmenopausal women. Sullivan argued this might 
be due to lower iron stores through iron loss in menstruation, suggesting that iron depletion has 
a protective role against ischemic heart disease. In addition, this suggested protection in women 
decreases after menopause when body iron store levels increase. 
 
1.3 Metabolism of iron 
Iron is a vital mineral that is necessary in the majority of cells of the human body such as in the 
production of red blood cells, use in the muscle tissue and in the synthesis of DNA (50). It is 
essential to regulate the metabolism of iron in the body, both due to its function and its possible 
noxious effects, and it includes steps regarding the process of intake, absorption, transport, 
usage, storage and loss of iron. On average each day, the human body absorbs and loses 1 to 2 
mg of iron (51). Iron is obtained from the diet, absorbed in duodenum wall and lost only 
passively through blood loss, sweat and loss of cells from the intestine, skin and urine (52). Iron 
is a fundamental functional component of hemoglobin, which is the molecule that transports 
the oxygen. The majority of the body iron is found in hemoglobin (1800 mg) present in 
circulating erythrocytes and the rest of the iron is distributed in the cells of the liver (1000 mg), 
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in myoglobin (300 mg) and a smaller amount in the plasma transferrin (3 mg) (51). Transferrin 
is the molecule that transports and releases iron in the plasma according to the needs of the 
body (52). Serum transferrin is usually about 30% saturated with iron. In the case of iron excess 
in the body, the ferritin protein stores the iron in the liver (50). Serum ferritin has been used in 
the diagnostic and assessment of iron storage status since 1970s (53).  Levels of s-ferritin ≥15 
µg/L indicate that iron stores are present and higher levels reflect the amount of iron store 
whereas, low levels (<15 µg/L) indicate depleted iron stores (54). The production of transferrin 
is affect by the levels of ferritin, increasing when ferritin levels in the liver are low and 
decreasing when cellular ferritin is high (55). Ferritin is an cute phase protein and levels of s-
ferritin may be elevated in inflammation and infection processes (56). Despite the vast clinical 
use of s-ferritin, key issues related with its biology are yet not clear. 
 
1.4 Hypothetical pathway of iron, oxidative stress and vascular 
effect 
Free iron can be toxic due to its form in oxygen free radicals. The “free radical theory” was 
launched by Harman in 1956, who suggested that free radicals resulted from aerobic respiration 
(57). Iron among other metals can catalyze in vivo leading to oxidative reactions that along 
with aging effects is related with cellular damage. Oxidative stress refers to the increase of 
reactive oxygen species, which are superoxide anion, hydrogen peroxide and hydroxyl radicals 
(58). Elevated concentrations of these substances, in particular hydroxyl radicals, may cause 
cellular damage and vascular lesions, and have been involved in the pathogenesis of 
atherosclerosis (59). There is strong evidence that the oxidation of LDL cholesterol occurs in 
early stage of atherosclerosis. However, core issues remain unexplained as occurrence and 
location of LDL oxidation in vivo (60). Currently, the scientific support of atherogenesis 
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hypotheses process underlies in four issues. First, LDL oxidation contributes to atherogenesis 
process and is generated in vivo in arterial lesions (61). Second, oxidized LDL creates 
biological effects in vitro that may be critical in lesion development (62). Third, the use of 
antioxidants in different animals models show inhibition of LDL oxidation decreasing the 
atherogenesis process (63). And fourth, knockout experiments in mouse have supported the 
oxidation hypothesis (64).  
An experimental study demonstrated a high expression of ferritin genes in atherosclerotic 
lesions of human and animal tissues (65). Other experimental study recorded iron deposits in 
atherosclerotic lesions of the aorta tissues (66). A study in patients with carotid stenosis 
removed by surgery, showed association between s-ferritin and the catalytic iron form, the low 
molecular weight iron (LMWI) and oxidant damage (67). A recent study of the possible role of 
iron in vascular damage showed association between high levels of s-ferritin and wider retinal 
venules caliber (68). Epidemiological studies have shown an association between iron and 
prediction of cardiovascular events. The first prospective cohort study, conducted by Salonen, 
showed that high s-ferritin was a significant risk factor for myocardial infarction (69). The 
association between carotid atherosclerosis and s-ferritin was shown for the first time in the 
Bruneck Study (70). Later, the same team investigated the topic in a prospective study that 
confirmed these relationship, showing that s-ferritin was a strong predictor in atherosclerosis 
progression (71). Other studies have shown that high levels of s-ferritin were associated with 
carotid atherosclerosis (72), (73), (74). And a study showed that s-ferritin was a risk factor for 
stroke in postmenopausal women (75). Still, results from different studies have been conflicting 
whether iron status, particularly ferritin, is a predictor of cardiovascular events. A meta-
analyses did not show association between iron status and CHD (76). Moreover, findings from 
a later prospective study (17-year follow-up) showed a weak or no relationship between ferritin, 
stroke and CHD (77). Furthermore, a study including blood donation did not show association 
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between iron status and carotid atherosclerosis (78). And another study do not support the iron 
hypothesis in CVD incidence (79).   
 
1.5 Aims of the thesis 
The purpose of this thesis was to investigate whether iron status is associated with carotid 
atherosclerosis and determine the prevalence of disease in a population-based survey. This 
study may contribute to the clarification of this association and may add important knowledge 
to future studies. The aims of this master thesis are: 
 
1. To investigate the relationship between iron status and carotid atherosclerosis.  
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2 Material and methods 
2.1 The Tromsø Study 
The Tromsø study is a population-based prospective study of the municipality of Tromsø, 
located in North Norway. The study includes a total of seven surveys (Tromsø 1-7) carried out 
from 1974 to 2016 with 5-7 years apart (80). The major aim of the first survey was to identify 
the causes of CVD related mortality in men in northern Norway, with focus on its prevention. 
Women were included from the second survey and a broader set of diseases as cancer, 
osteoporosis, mental and neurological diseases have been included throughout the surveys (81). 
According to the official population registry, varying samples of the residents of the 
municipality of Tromsø have been invited to participate in the survey. Personal invitations were 
sent by mail enclosed with a questionnaire and information about the survey and the 
examinations. The questionnaires included information about chronic diseases and health 
conditions. From Tromsø 1 to 7, a total of 160 427 subjects were invited to participate in the 
study and a total of 114 397 attended the surveys, with the majority having repeated 
measurements (82). Tromsø 4-7 includes two visits, the visit 1 with questionnaires and basic 
measures and visit 2 with extended examinations performed 2-4 weeks later (81). The selection 
for visit 2 was a predefined random selection of all participants, but only those attending visit 
1 were invited to attend the visit 2. The surveys 1-5 had high attendance rates (over 75%), while 
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2.2 Study population and design 
We performed a cross-sectional study based on data from the fifth survey of the Tromsø study 
(Tromsø 5) conducted in 2001-2002, as this survey has measurements of both iron status and 
ultrasound of the carotid artery. The iron status was measured in visit 1 and the measurement 
of hemoglobin and the ultrasound examination were performed in visit 2. The participants of 
Tromsø 5 were selected and invited if they had attended the second visit of Tromsø 4 (1994-
95). In addition, a smaller group of subjects (N=1916) attended the survey as part of a national 
health study from the Norwegian Institute of Public Health (82). The survey had an attendance 
rate of 79% with 8130 attendees out of 10 353 invitees. Detailed information about the invited 
and attended subjects of the survey according with the age groups and sex is provided in the 
appendix of this thesis. A total of 5920 subjects attended the visit 2 and of these, a total of 5423 
subjects performed the carotid examination, which represents the study population of this 































Invited Tromsø 5  
N= 10 353                
Men  
N= 2 385 
 
N= 2 385  
N= 2 385  
  
 
Attended the survey  
N= 8 130            
Participated – visit 2 
N= 5 920             
 
Carotid ultrasound 
N= 5 423                      
 
Participated – visit 1    
N= 8 064               
Women  
N= 3 038 
 
 
 N= 3 038 
 
No carotid ultrasound examination (497) 
 
 
Withdrawn consent (66) 
 
 
Figure 3 Flow chart of the study population. 
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2.3 Measurements  
2.3.1 Iron status, hemoglobin and risk factors measurements   
Non-fasting blood samples were performed in the cubital vein of the participants in sitting 
position. It was used an automated blood cell counter to measure the blood cell counts (Coulter 
Counter, Beckman Coulter, Inc., Brea, CA) (83). All blood samples were analyzed at the 
Department of Clinical Chemistry of the University Hospital of North Norway in Tromsø. The 
blood samples were analyzed within 24 hours. Before transportation to the laboratory, located 
at 1.4 km of distance, hematologic blood samples were stored at room temperature. The blood 
samples for the iron status were performed at visit 1 and include measurements of s-ferritin, 
transferrin saturation, s-iron, s-transferrin and s-total ironbinding capacity (TIBC). The blood 
samples for glycosylated hemoglobin (HbA1c), total and HDL cholesterol, triglycerides and 
glucose were also collected at visit 1. The samples for hemoglobin, c-reactive protein (CRP), 
white blood cells (WBC), fibrinogen and thrombocytes were drawn at visit 2. 
Measurements of s-ferritin, s-iron and s-transferrin were conducted on a Hitachi 917 analyzer 
from Boehringer, Germany. The ferrozine method was used to measure the s-iron. S-ferritin 
and s-transferrin were measured by a turbidimetric assay. S-transferrin was reported in grams 
per liter (g/L), s-TIBC was calculated as s-TIBC µmol/L = 25.1 x s-transferrin. Transferrin 
saturation (%) was calculated as 100 x (s-iron/s-TIBC) (84). The analyses for triglycerides, total 
and HDL cholesterol were measured by standard enzymatic colorimetric methods and high 
sensitivity CRP was measured by a particle-enhanced immunoturbidimetric assay from Roche 
(Mannheim, Germany). The analyses for HbA1c were performed with Bayer DCA 2000 (Bayer 
AG, Leverkusen, Germany). 
All physical examinations were performed by trained personnel. Electronic scales were used 
for height and weight measurements and the participants were wearing light clothing and no 
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footwear. The BMI was calculated from the body weight in kilograms divided by the square of 
height in meters (kg/m2). The blood pressure was measured with an automatic device (Dinamap 
Vital Signs Monitor 1846 Criticon) three times at one minute intervals after two minutes of 
seated resting (85). The mean of the two last recordings was used in this study. 
 
2.3.2 Questionnaires 
Two different questionnaires were sent to citizens with age under 70 years and those with 70 
years and above (82). Moreover, it was asked to the subjects that attended the survey to 
complete and send back another questionnaire with additional information. These 
questionnaires as well as the invitation are provided in the appendix of this thesis. Self-reported 
questionnaires included information about CVD, diabetes mellitus, smoking habits, alcohol 
consumption and use of medication. Self-reported myocardial infarction and/or stroke and/or 
angina pectoris were defined as CVD. Presence of diabetes was defined as self-reported 
diabetes and/or HbA1c ≥6.5. 
 
2.3.3 Carotid ultrasound examination  
The ultrasound examination was performed on the right carotid by four different examiners. 
The equipment used was an duplex scanner (Acuson Xp10 128 ART-upgraded) with a linear 
array 7.5-MHz transducer (16). In order to obtain equal and standardized examination 
techniques, all examiners have participated in a pre-study training protocol during two months. 
The carotid examination was performed longitudinally in 6 locations, in the near and far walls 
of respectively the right common carotid artery (CCA), the bifurcation (bulb) and the internal 
carotid artery. An atherosclerotic plaque was defined as a localized protrusion into the lumen 
of the vessel wall of more than 50% compared to the adjacent IMT (38). A maximum of 6 
 
Page 17 of 47 
plaques were registered in each subject. Plaques and IMT were recorded at angles which 
provided the best view of plaque size and IMT (16). All plaque measurements were recorded 
on videotapes and the images were digitized through a video grabber card (meteor II/Matrox 
Intellicam). The Adobe Photoshop image-processing program (version 7.0.1) was used to 
calculate the plaque area. The plaque area was assessed by outlining the plaque perimeter 
manually with a cursor and the plaque area was calculated (39). The total plaque area (TPA) 
was calculated as the sum of all plaque areas (16). For the IMT measurement, it was used an 
automated R-triggered assessing the near and far walls of the CCA and the far wall of the bulb 
(86). In addition, an automated computerized edge-detection program was used to measure the 
IMT and the lumen diameter of the CCA. The program was developed by the Wallenberg 
Laboratory of the Sahlgrenska University Hospital in Gothenburg, Sweden (87), and it provides 
estimates of the mean IMT and lumen diameter, from 100 measurements along a predefined 10 
mm segment of the CCA and the bulb (16). The average of the mean IMT of the 3 locations 
was used in this study. Subjects with suspected carotid stenosis or presence of occlusion, were 
referred to the Department of Neurology at the University Hospital of North Norway. 
 
2.4 Data analyses  
The statistical analyses of this study was performed using the program of Statistical Package 
for the Social Sciences (SPSS) version 24.0 for Windows. The level of statistical significance 
was defined as double-sided p-value <0.05 for all analyses. All statistical analyses were based 
on cases with complete data on all variables in the respective models.  
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The data analyses included descriptive and analytical statistics. To test the mean difference of 
the baseline characteristics between the sexes (Table 1), it was performed the Student´s t-test 
(independent-samples T test) for continuous variables with parametric distribution, whereas 
continuous variables with non-parametric distribution were analyzed by Mann-Whitney U test. 
The Chi-square test was used to test differences between categorical variables. Categorical 
variables were presented as percentages and normal distributed continuous variables were 
presented as mean with standard deviation. Due to non-parametric distribution, the variables of 
age, TPA, triglycerides, s-ferritin and CRP were presented as median and interquartile range. 
The dependent (outcome) variable, carotid atherosclerosis, was investigated in continuous and 
categorical variables that are: 1) total mean IMT; 2) TPA; 3) plaque presence (yes/no); and 4) 
high plaque load (≥3 plaques/no plaque). The independent (exposure) variables were 
hemoglobin, s-ferritin, transferrin saturation and s-TIBC. Dichotomized plaque outcomes were 
analyzed with multiple binary logistic regression models. Continuous carotid outcomes (total 
mean IMT and TPA) were analyzed with multiple linear regression models. Exposure variables 
were analyzed in separate models for each outcome to avoid multicollinearity. 
Assumptions were checked for the dependent and independent variables in multiple linear 
regression and logistic regression. The histogram from the total mean IMT variable, showed 
slight skewness to the right with several outliers and thus, data was logarithm transformed to 
approximate normal distribution. Data from TPA variable was not normally distributed, being 
also logarithm transformed to approximate normal distribution. Due to non-parametric 
distribution, with skewness to the right and presence of outliers, s-ferritin was log-transformed 
and if significantly associated also presented as quartiles with the lowest quartile as the 
reference. The data transformations were performed using the natural log and are provided in 
the appendix of this thesis.  
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We choose a priori to perform stratification by sex in all multivariate analyses because the 
levels of iron status and hemoglobin were lower in women than in men. In addition, there was 
significant interaction between sex and hemoglobin and between sex and age. 
The association between iron and carotid atherosclerosis was examined in three models. The 
model 1 was adjusted by age. The model 2 included adjustment for traditional cardiovascular 
risk factors (age, systolic and diastolic BP, smoking, total and HDL cholesterol, BMI and 
HbA1c). And the model 3 included adjustment for traditional cardiovascular risk factors and 
WBC. Daily smoking was categorized as never, previous and current smokers with never 
smokers as the reference.  
The same predictors were entered for men and women for each dependent variable, in order to 
compare results from the models. The variables of systolic and diastolic BP, total and HDL 
cholesterol, smoking, BMI and HbA1c were included in the analyses of plaque presence, high 
plaque load and IMT. In the analyses of TPA, the variables included were systolic and diastolic 
BP, HDL cholesterol, smoking and HbA1c. It was checked that in the association between 
hemoglobin and TPA in men, adding total cholesterol and BMI to the model did not change 
the statistical significance (p=0.003).  
In the preliminary assessment of possible confounders, it was performed correlation tests 
between the outcome and the factors of age, systolic and diastolic BP, smoking, total and HDL 
cholesterol, triglycerides, BMI, HbA1c, CRP and alcohol consumption. In addition, correlation 
tests between the same factors and the iron status and hemoglobin were conducted. Then the 
criteria to include a candidate confounder in the multivariable analyses was based on the 
variables that had p-value <0.1. We observed that the variables of age, systolic and diastolic 
BP, smoking, total and HDL cholesterol, BMI, HbA1c and WBC were strong predictors to 
carotid plaque. Despite triglycerides and alcohol consumption were significantly correlated 
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with iron status and hemoglobin, they were not considered to be candidate confounders due to 
the p-values >0.1 in the multivariate analyses. 
Ferritin is an acute phase response protein and so, its levels can be elevated in the presence of 
inflammation and infection (56). The c-reactive protein (CRP) is an inflammatory marker 
commonly used in the clinical area. We observed that CRP was significantly correlated with 
iron status and hemoglobin, though in the multivariable analyses the p-value was above 0.1. In 
addition, the change effect of CRP on the risk estimate in terms of odds ratio (OR) was below 
10% (88). Moreover, we checked that the adjustment for CRP did not change the estimates of 
the iron parameters association with carotid plaque. Therefore, CRP was not considered to be 
a candidate confounder. On the other hand, the WBC were included in a third model because it 
was a significant predictor of carotid plaque especially among men in almost all multivariate 
analyses. This may reflects the inflammation response in atherosclerosis (89).   
 
2.5 Ethical consideration and consent   
Confidentiality and professional secrecy of all information of the participants from the Tromsø 
study have been assured by the professionals involved. The study complies the Declaration of 
Helsinki. The Data Inspectorate of Norway and the Regional Committee for Medical Research 
Ethics (REK) have approved the Tromsø study. Informed consent was signed by all subjects 
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3 Results  
3.1 Baseline characteristics 
The characteristics of the study subjects at baseline are shown in the table 1. Men had higher 
TPA and IMT than women. Men had also higher levels of hemoglobin, s-ferritin and transferrin 
saturation than women. A considerable percentage of the participants were using BP lowering 
drugs, though the mean of systolic BP was high. Women had higher levels of total and HDL 
cholesterol than men, though the use of cholesterol lowering drugs was higher among men. The 
prevalence of diabetes was higher in men than in women and both sexes were similarly current 
smokers. The mean of BMI was equal in both sexes and the subjects were overweight. Subjects 
were aged between 32 to 89 years. 
Table 1 Baseline characteristics of study subjects by sex. 
 N  Women N Men p-value‡ 
Age, years† 3038 66.0 (13.0) 2385 67.0 (10.0) 0.1  
Total plaque area, mm2 † 3022 5.3 (16.8) 2371 11.9 (28.7)  <0.0001  
Intima-media thickness, mm  2964 0.8 (0.2)  2344 0.9 (0.2) <0.0001  
Systolic BP, mmHg  3036 143.5 (22.9)  2384 143.5 (20.6)  0.9  
Diastolic BP, mmHg 3036 80.7 (13.0) 2384 82.5 (11.9)  <0.0001 
Current BP lowering drugs   742 25.1%  609 26.2%  0.6 
Current  smokers  776 25.8%  604 25.4%  <0.0001 
Diabetes mellitus  129 4.4%  117 5.0%  0.3 
BMI, kg/m2  3024 26.8 (4.6) 2369 26.8 (3.5)   0.7 
Total cholesterol, mmol/L 3027 6.5 (1.2) 2378 6.1 (1.1)  <0.0001 
HDL cholesterol, mmol/L  3026 1.6 (0.4) 2378 1.4 (0.4)  <0.0001 
Triglycerides, mmol/L † 3027 1.3 (0.8) 2378  1.4 (1.0) <0.0001 
Current cholesterol lowering drugs  366 12.6%  418 18.2%  <0.0001 
Hemoglobin, g/dL  2654 13.5 (0.9) 2135 14.5 (1.1)  <0.0001 
HbA1c, %  2951 5.4 (0.8) 2342  5.6 (0.8) <0.0001 
Serum ferritin, µg/L† 2886 65.0 (63.0) 2258 96.0 (98.0) <0.0001 
Serum transferrin, g/L  2916 2.7 (0.4) 2289 2.6 (0.4)  0.004  
Transferrin saturation, % 2915 25.4 (9.2) 2289 26.9 (9.6)  <0.0001 
Serum iron, µmol/L 2915 16.7 (5.5) 2291 17.5 (5.8)  <0.0001 
Serum TIBC, µmol/L 2916 67.2 (10.1) 2289 66.5 (10.0)  0.004  
C-reactive protein, mg/L † 2979 1.5 (2.4) 2360  1.6 (2.3) 0.045  
White blood cells, 10 e9/L 2653 6.3 (1.8) 2134 6.4 (1.9) 0.017 
*Continuous variables presented as mean (standard deviation) and categorical variables as %. 
† Median (interquartile range) due to non-parametric distribution. 
‡ Test for difference between sex, analysed by Student´s t-test for continuous variables and parametric distribution. Continuous variables and 
non-parametric distribution analysed by Mann-Whitney U test. Categorical variables analysed by chi-square test.  
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The traditional cardiovascular risk factors of the study subjects with and without carotid plaque 
are shown in the table 2. The participants with plaque had higher systolic and diastolic BP than 
those without plaque. The frequency of current smokers was lower among the subjects without 
plaque than those with plaque. The participants with plaque had elevated history of stroke and 
higher prevalence of diabetes than those without plaque. The subjects without plaque had lower 
levels of total cholesterol and triglycerides than those with plaque and the mean of HDL 
cholesterol was equal across the two groups.    
Table 2 Cardiovascular risk factors of study subjects with and without carotid plaque. 
 N With plaque N Without plaque p-value‡ 
Systolic BP, mmHg  3260 147.7 (21.8)  2160 137.1 (20.3)  <0.0001     
Diastolic BP, mmHg  3260 82.4 (13.0)  2160 80.2 (11.7)  <0.0001     
Current smokers  889 64.4% 491  35.6%  <0.0001     
Diabetes mellitus 171 69.5% 75  30.5% 0.002  
HbA1c, % 3180 5.6 (0.8) 2113 5.4 (0.7) <0.0001     
History of stroke 180 78.6% 49 21.4% <0.0001     
BMI, kg/m2  3244 26.8 (4.1) 2149   26.8 (4.3) 0.9  
Total cholesterol, mmol/L  3252 6.4 (1.2) 2153  6.2 (1.1)  <0.0001     
HDL cholesterol, mmol/L 3252 1.5 (0.4)  2152 1.5 (0.4)   0.019 
Triglycerides, mmol/L† 3252 1.4  2153  1.3 <0.0001     
*Continuous variables presented as mean (standard deviation) and categorical variables as %. 
† Median (interquartile range) due to non-parametric distribution. 
‡ Test for difference between subjects with and without carotid plaque, analysed by Student´s t-test for continuous variables and 
parametric distribution. Continuous variables and non-parametric distribution analysed by Mann-Whitney U test. Categorical variables 
analysed by chi-square test.  
 
3.2 Prevalence of carotid plaque  
Atherosclerotic plaque was observed in 1648 women and in 1615 men (Table 3). The 
prevalence of carotid plaque was 54.2% in women and 67.7% in men with significant statistical 
difference between the two groups. Men had higher plaque load than women, where 25% had 
3 or more plaques compared with 18% of the women. The presence of only one plaque was 
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Table 3 Prevalence of carotid plaque and number of plaques in men and women. 
 Women Men p-value‡ 
 N % N %  
Carotid plaque     <0.0001 
    No 1390 45.8% 770 32.3%  
    Yes 1648 54.2% 1615 67.7%  
    Total 3038 100% 2385 100%  
      
Number of plaques     <0.0001 
    1 plaque 830 50.4% 697 43.2%  
    2 plaque 521 31.6% 515 31.9%  
    ≥ 3 plaques 297 18.0% 403 25.0%  
    Total 1648 100% 1615 100%  
* Categorical variables presented as %. 
‡ Test for difference between sex, analyzed by chi-square test. 
 
The number of subjects with atherosclerotic plaque increased with age in both men and women, 
increasing rapidly from the age of 60 years and declining from the age of 75 years, where the 
plaque predominance was in women. The figure 4 illustrates the distribution of the number of 
subjects with carotid plaque by equal age groups in men and women. 
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The total mean IMT and TPA were higher in men than in women, increasing substantially with 
age in both sexes. There was a linear increase in IMT with age in women and in TPA in men. 
In women, the plaque area increased substantially after the age of 59 years. These relationships 
are presented in the figure 5. 
    
Figure 5 Line graphs of total mean IMT and TPA by age (years) groups in men and women. 
 
Interaction terms were performed and it was observed that sex*hemoglobin was statistically 
significant in the association with TPA (p=0.002). Likewise, the interaction sex*age was also 
statistically significant in the association between hemoglobin and plaque presence (p=0.028), 
and in the association between s-ferritin and high plaque load (p=0.023).   
 
3.3 Association between iron and carotid atherosclerosis 
It was found association between iron stores and hemoglobin and carotid plaque, which it was 
most consistent in women. High levels of iron seem to be protective of plaque presence, high 
plaque load and plaque area.  
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Hemoglobin was negatively associated with plaque presence and high plaque load in women 
in both multivariate adjustment models, as shown in Table 4 and Table 5. It seems that 
hemoglobin had a protective effect in plaque presence and in high plaque load in women, being 
reduced by 11.3% odds (OR=0.887, 95% CI=0.802 to 0.980) and by 18.3% odds (OR=0.817, 
95% CI=0.674 to 0.989) respectively, per 1 unit increase in hemoglobin compared to men. In 
men, there was no association between hemoglobin and plaque presence (OR=1.0, 95% 
CI=0.935 to 1.149), and between hemoglobin and high plaque load (OR=0.873, 95% CI=0.745 
to 1.022). However, there was a negative significant association between hemoglobin and 
plaque area in men, independent of adjustment models (Table 6). The significant association 
between hemoglobin and plaque area in women in the model adjusted for age, was explained 
by confounding of cardiovascular risk factors which were, high systolic BP, low HDL 
cholesterol, high HbA1c and smoking.  
S-ferritin was negatively associated with plaque presence only in women and the association 
was strengthened with the adjustment models. Both s-ferritin log-transformed and s-ferritin 
quartiles had an inverse significant association with plaque presence. In model 3, the third (66-
102 µg/L) and the fourth (>103 µg/L) quartiles of s-ferritin showed reduced odds by 27.2 % 
(OR=0.728, 95% CI= 0.562 to 0.944) and by 27.6% (OR=0.724, 95% CI=0.558 to 0.939) 
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Table 4 Associations between plaque presence (yes versus no) and hemoglobin, s-ferritin log-transformed, s-
ferritin quartiles, transferrin saturation and s-TIBC in models 1, 2 and 3. 
Plaque, yes versus no  Women  Men 
 N OR P 95%CI N OR P 95%CI 
Model 1         
Hemoglobin, g/L 2654 0.988 0.799 0.903 to 1.082 2135 1.052 0.289 0.958 to 1.155 
Log-ferritin, µg/L 2886 0.904 0.064 0.813 to 1.006 2258 0.997 0.966 0.885 to 1.124 
Quartiles s-ferritin, µg/L  2886    2258    
      1.Q reference         
      2.Q  0.876 0.261 0.695 to 1.104  0.922 0.555 0.705 to 1.207 
      3.Q  0.829 0.109 0.659 to 1.043  1.147 0.323 0.874 to 1.507 
      4.Q  0.841 0.139 0.668 to 1.058  0.879 0.343 0.674 to 1.147 
      Linear trend over Q 2886 0.945 0.126 0.879 to 1.016 2258 0.981 0.662 0.902 to 1.068 
Transferrin saturation, % 2915 0.987 0.003 0.978 to 0.996 2289 0.997 0.582 0.988 to 1.007 
S-TIBC, µmol/L 2916 1.014 0.001 1.005 to 1.022 2289 1.002 0.754 0.992 to 1.011 
         
Model 2         
Hemoglobin, g/L 2551 0.891 0.024 0.806 to 0.985 2073 1.044 0.411 0.942 to 1.157 
Log-ferritin, µg/L 2800 0.885 0.032 0.791 to 0.990 2207 0.996 0.944 0.879 to 1.128 
Quartiles s-ferritin, µg/L  2800    2207    
      1.Q reference         
      2.Q  0.913 0.461 0.717 to 1.163  0.912 0.516 0.691 to 1.204 
      3.Q  0.808 0.082 0.635 to 1.028  1.135 0.380 0.855 to 1.506 
      4.Q  0.818 0.104 0.643 to 1.042  0.867 0.314 0.657 to 1.144 
      Linear trend over Q 2800 0.931 0.065 0.863 to 1.005 2207 0.977 0.613 0.895 to 1.068 
Transferrin saturation, % 2828 0.988 0.011 0.979 to 0.997 2237 0.999 0.878 0.989 to 1.009 
S-TIBC, µmol/L 2829 1.012 0.009 1.003 to 1.021 2237 0.999 0.812 0.989 to 1.009 
         
Model 3         
Hemoglobin, g/L 2550 0.887 0.019 0.802 to 0.980 2072 1.036 0.498 0.935 to 1.149 
Log-ferritin, µg/L 2451 0.833 0.033 0.739 to 0.940 1973 0.970 0.649 0.850 to 1.107  
Quartiles s-ferritin, µg/L  2451    1973    
      1.Q reference         
      2.Q  0.865 0.271 0.667 to 1.120  0.864 0.330 0.645 to 1.159 
      3.Q  0.728 0.017 0.562 to 0.944  1.082 0.606 0.802 to 1.459 
      4.Q  0.724 0.015 0.558 to 0.939  0.820 0.186 0.612 to 1.100 
      Linear trend over Q 2451 0.893 0.007 0.823 to 0.970 1973 0.962 0.418 0.877 to 1.056 
Transferrin saturation, % 2476 0.984 0.001 0.974 to 0.994 2001 0.998 0.682 0.987 to 1.009 
S-TIBC, µmol/L 2477 1.015 0.002 1.005 to 1.024  2001 1.003 0.584 0.992 to 1.014 
Model 1: adjusted for age and stratified by sex. 
Model 2: adjusted for age+systolic and diastolic BP+smoking (categorical)+BMI+total and HDL chol.+HbA1c and stratified by sex. 
Model 3: adjusted for age+systolic and diastolic BP+smoking (categorical)+BMI+total and HDL chol.+HbA1c+WBC and stratified by  sex. 
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Table 5 Associations between high plaque load (≥3 plaques versus no plaque) and hemoglobin, s-ferritin log-
transformed, s-ferritin quartiles, transferrin saturation and s-TIBC in models 1, 2 and 3. 
Plaque-load  Women  Men 
 N OR P 95%CI N OR P 95%CI 
Model 1         
Hemoglobin, g/L 1467 0.997 0.969 0.846 to 1.174 1044 0.944 0.398 0.825 to 1.080 
Log-ferritin, µg/L 1606 0.809 0.033 0.665 to 0.983 1115 0.902 0.251 0.757 to 1.076 
Quartiles s-ferritin, µg/L 1606    1115    
      1.Q reference         
      2.Q  0.814 0.323 0.541 to 1.224  0.742 0.138 0.500 to 1.101 
      3.Q  0.670 0.060 0.441 to 1.017  1.072 0.730 0.723 to 1.590 
      4.Q  0.643 0.037 0.424 to 0.974  0.647 0.034 0.433 to 0.968 
      Linear trend over Q 1606 0.859 0.024 0.753 to 0.981 1115 0.911 0.150 0.803 to 1.034 
Transferrin saturation, % 1621 0.986 0.085 0.969 to 1.002 1130 0.998 0.738 0.983 to 1.012 
S-TIBC, µmol/L 1621 1.027 0.000 1.012 to 1.043 1130 1.005 0.493 0.991 to 1.018 
         
Model 2         
Hemoglobin, g/L 1408 0.823 0.046 0.681 to 0.996 1012 0.893 0.157 0.763 to 1.045 
Log-ferritin, µg/L 1559 0.754 0.010 0.608 to 0.935 1088 0.882 0.198 0.728 to 1.068 
Quartiles s-ferritin, µg/L 1559    1088    
      1.Q reference         
      2.Q  0.787 0.297 0.501 to 1.235  0.674 0.066 0.442 to 1.027 
      3.Q  0.587 0.026 0.367 to 0.938  1.049 0.824 0.686 to 1.605 
      4.Q  0.562 0.014 0.355 to 0.889  0.603 0.024 0.388 to 0.937 
      Linear trend over Q 1559 0.818 0.007 0.707 to 0.947 1088 0.901 0.137 0.785 to 1.034 
Transferrin saturation, % 1574 0.983 0.060 0.965 to 1.001 1103 0.997 0.664 0.982 to 1.012 
S-TIBC, µmol/L 1574 1.030 0.000 1.014 to 1.047 1103 1.007 0.334 0.993 to 1.022 
         
Model 3         
Hemoglobin, g/L 1408 0.817 0.038 0.674 to 0.989 1011 0.873 0.092 0.745 to 1.022 
Log-ferritin, µg/L 1360 0.707 0.004 0.560 to 0.892 970 0.858 0.146 0.697 to 1.055 
Quartiles s-ferritin, µg/L 1360    970    
      1.Q reference         
      2.Q  0.645 0.079 0.395 to 1.052  0.694 0.110 0.443 to 1.086 
      3.Q  0.454 0.003 0.272 to 0.758  1.101 0.678 0.699 to 1.734 
      4.Q  0.471 0.003 0.286 to 0.774  0.587 0.027 0.366 to 0.943 
      Linear trend over Q 1360 0.775 0.002 0.660 to 0.909 970 0.898 0.153 0.775 to 1.041 
Transferrin saturation, % 1373 0.983 0.092 0.964 to 1.003 983 0.996 0.612 0.980 to 1.012 
S-TIBC, µmol/L 1373 1.032 0.000 1.014 to 1.051 983 1.011 0.167 0.995 to 1.027 
Model 1: adjusted for age and stratified by sex. 
Model 2: adjusted for age+systolic and diastolic BP+smoking(categorical)+BMI+total and HDL chol.+HbA1c and stratified by sex. 
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Table 6 Associations between TPA log-transformed and hemoglobin, s-ferritin log-transformed, transferrin 
saturation and s-TIBC in models 1, 2 and 3. 
Log-TPA  Women  Men 
 N B P 95%CI N B P 95%CI 
Model 1         
Hemoglobin, g/L 1424   0.047 0.018 0.008 to 0.085 1433 -0.038 0.033 -0.074 to -0.003 
Log-ferritin, µg/L 1548   0.023 0.336 -0.023 to 0.069 1506 -0.023 0.343 -0.07 to 0.024 
Transferrin saturation, % 1566  -0.001 0.763 -0.005 to 0.003 1526 -0.002 0.416 -0.005 to 0.002 
S-TIBC, µmol/L 1567 0.003 0.138 -0.001 to 0.006 1526 -0.0004 0.842 -004 to 0.003 
         
Model 2         
Hemoglobin, g/L 1374   0.013 0.516 -0.026 to 0.053 1398 -0.056 0.002 -0.092 to -0.021 
Log-ferritin, µg/L 1505   0.014 0.537 -0.031 to 0.060 1481 -0.024 0.310 -0.071 to 0.023 
Transferrin saturation, % 1522 -0.0003 0.888 -0.004 to 0.004 1500 0.0002 0.918 -0.004 to 0.004 
S-TIBC, µmol/L 1523 0.003 0.157 -0.001 to 0.006 1500 -0.001 0.574 -0.005 to 0.003 
         
Model 3         
Hemoglobin, g/L 1373   0.013 0.533 -0.027 to 0.052 1397 -0.059 0.001 -0.095 to -0.024 
Log-ferritin, µg/L 1316   0.017 0.497 -0.032 to 0.066 1323 -0.028 0.260 -0.077 to 0.021 
Transferrin saturation, % 1331   0.001 0.772 -0.004 to 0.005 1342 0.001 0.778 -0.004 to 0.005 
S-TIBC, µmol/L 1332 0.002 0.388 -0.002 to 0.005 1342 -0.001 0.498 -0.005 to 0.003 
Model 1: adjusted for age and stratified by sex. 
Model 2: adjusted for age+systolic and diastolic BP+smoking(categorical)+HDL chol.+HbA1c and stratified by sex.  
Model 3: adjusted for age+systolic and diastolic BP+smoking(categorical)+HDL chol.+HbA1c+WBC and stratified by sex. 
 
Furthermore, we found a negative consistent association between s-ferritin and plaque load in 
women in both analyses of log-transformed s-ferritin and quartiles, being strengthened with 
multivariate adjustment models. In model 3, the third and the fourth s-ferritin quartiles showed 
reduced odds by 54.6 % (OR=0.454, 95% CI= 0.272 to 0.758) and by 52.9% (OR=0.471, 95% 
CI=0.286 to 0.774) respectively, compared with the lowest s-ferritin quartile. In men, there was 
a significant negative association between the highest (>153 µg/L) compared to lowest (≤54 
µg/L) s-ferritin quartile and plaque load that was independent of adjustment models. Although, 
this association was not as consistent as in women, as there was no linear trend over quartiles 
and no significant association in s-ferritin log-transformed. Moreover, there was no association 
between s-ferritin and plaque area neither in women nor in men. 
Transferrin saturation was negatively associated with plaque presence only in women, that was 
strengthened by the adjustment models, suggesting reduced odds by 1.6% (OR=0.984, 95% 
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CI=0.974 to 0.994) per 1 unit increase in transferrin saturation compared to men. There was no 
association between transferrin saturation and high plaque load and plaque area neither in 
women nor in men. Furthermore, there was no association between iron stores and hemoglobin 
and IMT (Table 7). The significant association between hemoglobin and transferrin saturation 
and IMT among women in the model adjusted for age, was confounded by the factors of high 
systolic BP, low diastolic BP, smoking, high total cholesterol, low HDL cholesterol and high 
BMI. There was no association between s-TIBC and carotid atherosclerosis. 
 
Table 7 Associations between IMT log-transformed and hemoglobin, s-ferritin log-transformed, transferrin 
saturation and s-TIBC in models 1, 2 and 3. 
Log-mean IMT  Women  Men 
 N B P 95%CI N B P 95%CI 
Model 1         
Hemoglobin, g/L 2587 0.012 0.001 0.005 to 0.019 2099 0.002 0.535 -0.005 to 0.009 
Log-ferritin, µg/L 2820 0.002 0.646 -0.006 to 0.01 2220 -0.002 0.722 -0.011 to 0.008 
Transferrin saturation, % 2848 -0.001 0.005 -0.002 to -0.0003 2250 -0.001 0.184 -0.001 to 0.0002 
S-TIBC, µmol/L 2849 0.001 0.006 0.0002 to 0.001 2250 0.0001 0.694 -0.001 to 0.001 
         
Model 2         
Hemoglobin, g/L 2491 0.002 0.636 -0.005 to 0.009 2040 -0.006 0.113 -0.013 to 0.001 
Log-ferritin, µg/L 2737 -0.003 0.514 -0.011 to 0.005 2173 -0.007 0.113 -0.016 to 0.002 
Transferrin saturation, % 2765 -0.0005 0.151 -0.001 to 0.0002 2202 -0.0001 0.759 -0.001 to 0.001 
S-TIBC, µmol/L 2766 0.0002 0.458 -0.0004 to 0.001 2202 -0.0005 0.196 -0.001 to 0.0002 
         
Model 3         
Hemoglobin, g/L 2490 0.002 0.652 -0.005 to 0.009 2039 -0.007 0.083 -0.014 to 0.001 
Log-ferritin, µg/L 2395 -0.002 0.642 -0.010 to 0.007 1943 -0.009 0.072 -0.018 to 0.001 
Transferrin saturation, % 2420 -0.001 0.127 -0.001 to 0.0002 1970 0.0001 0.825 -0.001 to 0.001 
S-TIBC, µmol/L 2421 0.0002 0.539 -0.0004 to 0.001 1970 -0.0004 0.303 -0.001 to 0.0004 
Model 1: adjusted for age and stratified by sex. 
Model 2: adjusted for age+systolic and diastolic BP+smoking(categorical)+BMI+total and HDL chol.+HbA1c and stratified by sex. 
Model 3: adjusted for age+systolic and diastolic BP+smoking(categorical)+BMI+total and HDL chol.+HbA1c+WBC and stratified by sex. 
 
The association between s-ferritin and hemoglobin and plaque presence in women, was 
strengthened by age, systolic BP, smoking, high total cholesterol and low HDL cholesterol. In 
addition to these factors, high HbA1c was an important factor to strength the association 
between s-ferritin and high plaque load in women, whereas in the association between 
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hemoglobin and high plaque load, the important factors were age, systolic BP, smoking, low 
HDL cholesterol and high HbA1c. In men, the important factors that strengthened the 
association between s-ferritin and plaque presence were high age and systolic BP, low diastolic 
BP, smoking and WBC.  
We used the coefficient of determination, the R2, to assess the amount of variance in the 
outcome explained by the model in multivariate regression models. The higher values of the R2 
were observed when the cardiovascular risk factors were entered. The highest R2 values in terms 
of Cox & Snell R2 and Nagelkerke R2 was that 30.4% and 42.2% respectively, of the variance 
in high plaque load among men was explained by s-ferritin, age, systolic and diastolic BP, 
smoking, BMI, total and HDL cholesterol, HbA1c and WBC. In this model, the strongest 
predictors assessed by the highest Wald test values were age (85.4), smoking (36.0), systolic 
BP (25.8) and s-ferritin (8.9), followed by WBC (7.3), diastolic BP (7.1) and HbA1c (2.4), total 
cholesterol (1.7) and BMI (1.3).  
In all analyses, the strongest predictors to plaque presence and high plaque load were high age, 
high systolic BP and smoking. Smoking was a strong predictor to carotid atherosclerosis and 
its highest value in terms of OR was observed in the analyses of s-ferritin quartiles. In men, 
current smokers had 6 times increased odds (95% CI=3.857 to 10.806) of high plaque load 
compared to never smokers. And in women, current smokers had 5 times higher odds (95% 
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4 Discussion 
4.1 Methodological considerations 
4.1.1 Study design  
We performed a cross-sectional study which is an observational study that allows the 
investigation of the relationship between the exposure and the outcome, and the comparison of 
different groups in a representative sample at a single point in time (90). And so, it may well 
be used to measure the prevalence of carotid atherosclerosis and to examine the association 
between the iron status and disease. However, a cross-sectional study can not determine the 
disease etiology or causality of an association neither the relationship between risk factors and 
disease throughout the time. Our study was conducted in a representative sample and 
geographically defined, allowing sex-specific analyses that with the high attendance rates of 
the survey represent the major strengths of our study.  
 
4.1.2 Internal validity 
Validity is an important issue in epidemiological research and it can be defined as the extent of 
valid inferences taken from a study (91). There are two types of validity, the internal and the 
external validity. The internal validity is related with the extent of presence of bias or systematic 
errors in a study, and it depends on study methodology. Bias can be defined as a systematic 
deviation from the truth that weakens the internal validity of a study, leading to differential 
errors that may be different between groups (92). Usually, bias may occur in observational 
studies in three different categories that are selection bias, information bias and confounding, 




Page 34 of 47 
Selection bias 
The selection of the study subjects can lead to bias of the results. In the Tromsø 5 there was 
2223 persons (21%) that did not attend the survey (93). In addition, 497 subjects were excluded 
from the analyses because they did not perform the carotid examination for some reason, and 
66 persons have withdrawn their consent. There may be systematic differences between 
participants and non-participants. This phenomenon is called non-response bias and it may lead 
to differences in the relation of the exposure and the outcome between the two groups (92). 
Moreover, non-respondents of health surveys tend to be older, sicker and less educated. Thus, 
participants may possibly be healthier than the non-participants and so, it may occur the healthy 
participant effect (94). Nevertheless, the use of the official population registry in the Tromsø 
study to select the participants and the high attendance rate (79%) of the 5th survey, are 
important aspects to avoid selection bias. 
 
Information bias 
Information bias refers to the collection of the relevant information and the accuracy of the 
measurements (exposure, covariate or outcome), that can affect the quality of results (91). The 
carotid atherosclerosis was accurately measured through the ultrasound examination and other 
computer-assisted methods. Likewise, body iron status and potential confounders were 
accurately measured in blood samples and physical examinations. The objective and reliable 
measurements may minimize the information bias, which it can be considered as a strength of 
our study. However, it was used questionnaires to collect information about current diseases, 
history of CVD, smoking habits and alcohol consumption, among others. We can not 
completely exclude information bias, once self-reported information may affect the accuracy 
of the data collection and chance of misclassification. A further limitation is that the 
ultrasonography was performed only on the right carotid artery and it is known that carotid 
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atherosclerosis is a bilateral symmetrical disease (95). Thus, the examination of only one side 
of the artery may lead to loss of cases. Moreover, the ultrasound examination was performed 
on-line by four different examiners, which it may increase the chance to occur variability in the 
ultrasound reading (16). The overall reproducibility of plaque area was good with small inter-
observer differences in the mean values (arithmetic and absolute values). Although, the process 
of plaque outlining counted on systematic difference between two readers, making the 
computer-assisted on-line method prone to systematic bias (96). Furthermore, other limitation 
is the measurement of the iron status only at baseline and as it is known, the concentrations of 
the iron parameters have a considerable individual variability throughout time (97). Thus, 
repeated measurements of the iron indicators would have been more accurate. 
 
Confounding 
Confounding is considered to be a problem in epidemiological studies. It is defined as a third 
variable that is related with both the exposure and the outcome, which it can lead to an error in 
the estimate of the measure (90). In our study, control for confounding included the use of 
multivariable regression analyses with adjustment for the factors of age, sex, systolic and 
diastolic BP, total and HDL cholesterol, smoking, BMI, HbA1c and WBC. Likewise, it was 
used the stratification by sex to handle confounding.  
Despite, the multivariate models were adjusted for several confounders, we cannot exclude 
other candidate confounding factors such as the use of antioxidants like vitamins C and E and 
pharmacological antioxidants as aspirin. The use of antioxidants may have a role in the 
atherogenesis through the inhibition of LDL oxidation (63). 
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Missing data 
Epidemiological and medical research are prone to missing data. It refers to incomplete 
information in some variables of some study subjects that may lead to systematic differences 
between the missing and the observed data (91). We performed complete case analyses that 
refers to a case with any missing data for any of the variables is excluded from the analyses. 
This approach may lead to a reduction of number of cases included in the analyses (98). 
Moreover, it may decrease statistical power and biased estimates, if the assumption of missing 
completely at random (MCAR) is not meet. This assumption considers that there are no 
systematic differences between the observed and the missing values, though it is difficult to 
meet this assumption in practice (99). 
We observed a low amount of missing data in our study. In regard to our predictors of interest, 
we observed 4% of missing data for transferrin saturation (N=219) and for s-TIBC (N=218). S-
ferritin data was missing in 5% (N=279) and about 12% of the participants had missing values 
for hemoglobin (N=634). Missing data for the hemoglobin samples was higher due to 
transportation logistic reasons, where the blood samples drawn on the day before the weekend 
(after 1:00 pm) were not analyzed leading to a loss of 12% (N=667) of the blood samples (83).   
Regarding the covariates, there was no missing data for the variables of age and sex. Low 
percentages of missing data were observed in the variables of systolic and diastolic BP (0.1%), 
total and HDL cholesterol (0.3%, 0.4%), BMI (0.6%) and HbA1c (2.4%). Likewise, as in 
hemoglobin, about 12% (N=636) of the participants had missing values for WBC. The fact that 
about 12% of the participants had missing data for hemoglobin and WBC, may not have been 
substantial to bias the study population. In addition, the statistical power of our study may not 
have been affected because our sample is large and representative.   
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4.1.3 External validity 
The external validity is related with the extent that results from a study can be generalized to 
other populations in addition to the study subjects (91). Generalizability of the findings need to 
be cautious. There is need to ensure that populations are similar regarding socio-demographic 
characteristics such as age, sex, ethnicity, education and socioeconomic level (90). The results 
from our study may be generalized in Western populations with Caucasian ethnicity.   
 
4.1.4 Statistical considerations  
Effect modification (interaction)  
The effect modification or interaction occurs when the relation between the exposure and the 
outcome is modified by other factor, affecting the effect estimate (90). We choose a priori the 
stratification by sex in all analyses because the levels of iron status and hemoglobin vary 
considerably across sex, where women have lower levels compared to men of the same age, 
before and after the menopause (54). In addition, this strategy was chosen to handle the 
interaction effect. Various interaction terms were performed and it was observed that 
sex*hemoglobin and sex*age were statistically significant. Sex seems to act as a moderator 
with different effect in men and in women, modifying the relationships of hemoglobin and age 
with carotid plaque. 
 
Data transformation  
Continuous s-ferritin variable and carotid outcomes were logarithm transformed to approximate 
normal distribution. Data transformation is an useful tool however, it implies some challenges 
in terms of making inferences about the original data (100). Log data involves mathematical 
transformation of the mean represented by the geometric mean, which is defined as the antilog 
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of the arithmetic mean of log-transformed values (101). The logarithm of a number Y is defined 
as the power in terms of exponent, that a base number must be raised to obtain the original 
number. This can be expressed as, log (y)= elog(y) = Y. The interpretation of the estimated 
coefficient (β) in the log-linear model, expressed by the formula log(Yi) = α  + βXi + εi, is that 
each one-unit increase in X multiplies the expected value of Y by eβ (102). 
 
 
4.2 Findings  
4.2.1 Prevalence of carotid atherosclerosis 
The prevalence of carotid plaque tends to be higher among men than in women, increasing with 
aging in both sexes (26). Our study showed significant gender differences in the prevalence of 
atherosclerotic plaque, being higher in men (67.7%) than in women (54.2%). Men had also 
larger TPA and thicker intima media layer. Furthermore, the prevalence of carotid plaque 
increased with age in both sexes similarly although, women had a substantial increase of TPA 
after the age of 59 years that may be related with the establishment of menopause. Indeed, age 
and sex were strong and independent predictors of atherosclerotic plaque, which is in line with 
previous studies (26), (25). 
 
4.2.2 Association between iron status and carotid atherosclerosis 
All iron parameters were significantly associated with carotid plaque in both categorized and 
linear models. Our findings revealed that s-ferritin, transferrin saturation and hemoglobin were 
negatively associated with carotid plaque with consistent findings in women, suggesting that 
they were associated with lower risk of atherosclerotic plaque. High levels of s-ferritin were 
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associated with greater protective effect towards high plaque load, where the third and the 
fourth s-ferritin quartiles showed reduced odds by 54.6 % (OR=0.454, 95% CI= 0.272 to 0.758) 
and by 52.9% (OR=0.471, 95% CI=0.286 to 0.774) respectively, compared with the lowest s-
ferritin quartile. Hemoglobin had a protective effect in plaque presence and high plaque load in 
women, being reduced by 11.3% odds (OR=0.887, 95% CI=0.802 to 0.980) and by 18.3% odds 
(OR=0.817, 95% CI=0.674 to 0.989) respectively, per 1 unit increase in hemoglobin compared 
to men. We found no association between iron stores and hemoglobin and IMT.   
The risk factors of CVD have been extensively investigated in the past and it includes age, 
gender, hypertension, cigarette smoking, hypercholesterolemia, diabetes mellitus and obesity 
(5). Beyond these traditional risk factors, iron has been suggested to have a role in CVD (49). 
The Sullivan hypothesis and other studies showed a positive relation between iron stores and 
risk of CVD (72), (75), (73), while other studies were opposed. A meta-analyses showed an 
inverse association between transferrin saturation and CHD, and no significant association for 
other iron markers (103).  
Our surprising finding of high iron levels may confer a protective effect in atherosclerotic 
plaque led to a need to search for alternative explanations. There are few studies that suggest a 
negative association between iron status and CVD and this may be related with publication 
bias. Publication bias refers to systematic differences of results between the published and 
unpublished studies. Its occurrence is related when the publication of a study depends on the 
direction of its results, where there is a tendency to publish studies that suggested positive 
results than the studies that showed negative results (104), (105). The consequences of 
publication bias may be problematic due to difficulties in the interpretation of literature (106).   
Furthermore, the negative association between iron status and atherosclerosis found in our 
study may possibly be related with some biological mechanisms. The atherogenesis involves 
oxidative reactions, inflammatory responses and intervention of immune cells due to injury of 
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endothelial cells (13). Iron can catalyze in vivo leading to oxidative reactions that are related 
cellular damage, which has been involved in the atherogenesis (59). S-ferritin is considered to 
be the major indicator of total body iron stores (53). Ferritin may have a protection role from 
oxidative damage through the sequestration of iron (5). This is supported by experimental 
evidence that suggests that oxidative cell damage may be protected by ferritin (107), (108). 
Beyond that, there is strong evidence that in early atherogenesis, it occurs the accumulation of 
apolipoprotein B in the subendothelial space of the artery (17). Experimental studies suggested 
that ferritin may interact with various plasma proteins particularly, apolipoprotein B. The ability 
of ferritin binding with apolipoprotein B may lead to a decrease of apolipoprotein B secretion, 
suggesting a possible intersection of the metabolic pathways of iron storage and intercellular 
cholesterol (109), (110). This mechanism may also be related with our findings of high levels 
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5 Conclusion 
Our findings suggest that in this population, s-ferritin, transferrin saturation and hemoglobin 
were negatively associated with carotid atherosclerosis with consistent findings among women, 
suggesting a protective effect of iron in atherosclerosis. This way our results seem to be opposed 
to the Sullivan hypothesis. We also conclude that the prevalence of carotid atherosclerosis 
increased with age and it was higher in men than in women. 
The CVD represent a burden in public health as they are the main cause of mortality globally. 
It is necessary further epidemiological research on the possible role of iron in the CVD as this 
relationship has not been extensively explored, in order to achieve a better understanding of 
this issue. As this study is an observational study it is not possible to determine temporal and 
causal relations. We recommend future studies in prospective designs to assess the effect of the 
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  Welcome to the fifth round
  of the Tromsø Study!
-a collaboration between:
Department of Community Medicine, 
University of Tromsø
National Health Screening Service
You will find more information about the health survey on 




Would you like to participate in 
the fifth survey of the Tromsø study?  
Why a new round of 
the Tromsø study?                 
Large health studies were 
conducted in Tromsø in 1974, 
1979-80, 1986-87, and 1994-95. 
These surveys have given us 
important knowledge concerning 
cardiovascular epidemiology and 
other serious diseases, such as 
cancer. 
The main purpose of another 
Tromsø study is to monitor any 
changes in the health of the population since last survey. We will 
analyze the information we have about a person, both personal data 
and results from analysis of frozen blood, and see if there are 
relationships to diseases that occur. This way we learn more on how 
cardiovascular diseases, cancer and other major diseases develop 
and how they can be prevented. 
We ask everyone who participated in the Special Study in the Tromsø 
study in 1994-95 and a selection of others older than 29 years.
Why are we asking you to participate?
What does the study include?      
    The Tromsø study is first and foremost a 
research project. Through following up 
as many as possible from the study of 
1994-95, we gain valuable information of 
health and disease in the population of 
Tromsø. 
Participants’ general health status will be examined with regard to 
certain diseases and risk conditions. If you have a high risk of 
developing cardiovascular diseases you will be notified of this.
On the day of the examination you will be guided through the survey 
and there will be an opportunity to ask questions. Your height, weight 
and waist circumference is measured, as well as blood pressure, and a 
blood sample is taken. Your lung capacity is determined, in addition 
to simple tests of vision and strength. Tests to determine osteoporosis 
is are also conducted.
The blood sample may later be analyzed for fatty substances, blood 
sugar, indicators of infections, diet, hormones, liver- and kidney 
function, and bone markers.
The blood which is frozen will be used for medical research only, in 
order to find factors influencing disease. In most cases this means 
that data from people with a disease is compared to data from those 
without it. The comparison is done on already collected data and the 
new analysis from the frozen blood.
With this letter a questionnaire is attached. We kindly ask you to 
complete this form at home and bring it on the day of the 
examination.
Everyone who participated in the Special Study in 1994-95 is also 
offered to take part in another Special Study. This study provides 
information on the heart and the main arteries in neck and abdomen, 
and offers a more detailed analysis on tendency of osteoporosis. 
This survey is also located at the Elisabeth-center in Tromsø. A time 
will be scheduled for you and information is provided upon arrival. 
If you are unsure of how to answer a question, leave it blank. You 
will be aided at the examination.
Everyone who participates in the study will be given an additional 
questionnaire of other factors which might affect your health. The 
questionnaire is to be completed at home and sent to the National 
Health Screening Service in the enclosed envelope.
We might want to analyze parts of the DNA from the frozen blood 
cells. Because DNA is important for the regulating and development 
in human being, we need knowledge on DNA to understand why 
diseases evolve. Analysis of this kind are only conducted after the 
Data Inspectorate has given a permission and if The Regional 
Committee for Research Ethics has no objections to the analysis. 
The Questionnaires
Future analysis of blood
Where are you going to meet?
The survey will for the vast majority take 
place in Elizabeth Center in Tromsø. For some 
of the outer places in the municipality, the 
survey will take place locally. Those 
concerned are notified in this letter.
On the front page of the questionnaire that you 
receive with this letter are the opening hours 
for the health survey and when you have to 
attend the survey. If you cannot attend at that 
time, you are welcome any another time 
during the opening hours of the survey. There 
is no need to tell us about this ─ just show up 
when we are open.
When will you receive your results?  
That the results, after legal approval from the Data Inspectorate, may 
be linked with information about you in other registries, to be used for 
research purposes. This might be registries including information on 
health, pension and disease, and also data on income, education and 
occupation, in addition to information from previous health studies in 
Tromsø. Examples of such registries are the Cancer Registry, the 
Cause of Death registry and population censuses. In these cases your 
name and social security number are removed when data is analyzed. 
When you attend the study, you will be asked to sign a consent form 
where  you agree to the following six points:
That we may contact you with recommendations of follow ups, 
treatment or prevention of disease.
That we may ask you to participate in similar studies in the future.
That we may use the results for medical research.
That the blood sample may be stored and used for medical 
research. All use of this sample will only take place after approval 
from the Data Inspectorate and if The Regional Committees for 
Research Ethics has no objections. 
That the blood sample may also be used for analysis of DNA.
Even if you approve to this now, you are entitled to change your 
opinion later and also ask to have your profile deleted from the 
registry. You may also decline to consent to one or more of the points 
above. The Data Inspectorate has given consent to this fifth survey of 
the Tromsø Study, and the Regional Committee for Research Ethics 
has no objections. We keep your results confidential and safe. 
Everyone employed in the Tromsø Study has signed a confidentiality 
agreement. 
About four weeks after you participated in the study you will receive 
a letter wherein your recorded values for cholesterol, blood pressure 
and blood sugar are stated. You will also receive more information 
on the different risk factors.
People who are found to be at particularly high risk of developing 
cardiovascular diseases and diabetes will be recommended to seek 
further examination from their own doctor.

















5.3 (Municipality) (County) (Country)
9.3 (Business) 9.4 (Occupation) 14.7 (Mark)






Fibromyalgia/chronic pain syndrome ......
Psychological problems for which you  
have sought help  ............................................
A heart attack .........................................
Angina pectoris (heart cramp) ................
Cerebral stroke/brain haemorrhage .........
2.1 Have you suffered from pain and/or stiffness in 
muscles and joints during the last 4 weeks?
(Give duration only if you have had problems)
5.1 How long altogether have you lived in the county?
(Put 0 if less than half a year)
5.2 How long altogether have you lived in the municipality?
(Put 0 if less than half a year)
5.3 Where did you live most of the time before the age of 16?
(Tick one option and specify)
Same municipality ....
Another municipality
in the county .............. Which one:
Another county in Norway Which one:
Outside Norway ........ Country::
5.4 Have you moved within the last five years?
No Yes, one time Yes, more than once
1           2       3
NoYes
1.1 What is your current state of health? (Tick one only)
Poor Not so good Good Very good
1                  2               3           4
1.4 Do you get pain or discomfort in the chest when:
Walking up hills, stairs or walking fast on level ground?
1.6 If you stop, does the pain disappear within
10 minutes? ...........................................................
1.7 Can such pain occur even if you are at rest?........
1.5 If you get such pain, do you usually:
Stop? Slow down? Carry on at the same pace?









Upper part of your back... 
Lumbar region .................
Hips, legs, feet ................
Other places ....................











2.2 Have you ever had:
Fracture in the wrist/forearm  ...................
Hip fracture?..............................................
1. YOUR OWN HEALTH 3. OTHER COMPLAINTS
4. USE OF HEALTH SERVICES
5. CHILDHOOD/YOUTH AND AFFILIATION
6. BODY WEIGHT
2. MUSCULAR AND SKELETAL COMPLAINTS
3.1 Below is a list of various problems. Have you experienced 
any of this during the last week (including today)?
(Tick once for each complaint)
Sudden fear without reason ....................
Felt afraid or anxious ..............................
Faintness or dizziness ............................
Felt tense or upset ..................................
Tend to blame yourself ...........................
Sleeping problems ..................................
Depressed, sad ......................................
Feeling of being useless, worthless ........
Feeling that everything is a struggle ......










1             2            3           4
4.1 How many times in the last 12 months have you been to/used:
(Tick once for each line)
General practitioner (GP) .......................
Medical officer at work ...........................
Psychologist or psychiatrist ....................
(private or out-patient clinic)
Other specialist (private or out-patient clinic)
Emergency GP (private or public) ..............
Hospital admission .................................











6.1 Estimate your body weight when you
were 25 years old: kg
1.3 Have you noticed attacks of sudden changes in  









7. FOOD AND BEVERAGES 8. SMOKING
9. EDUCATION AND WORK
7.1 How often do you usually eat these foods?
(Tick once per line)
7.2 What type of fat do you usually use? (Tick once per line)
7.3 Do you use the following dietary 
supplements:
8.1 How many hours a day do you normally spend
in smoke-filled rooms? Number of total hours
8.2 Did any of the adults smoke at home 
while you were growing up? .................................
8.3 Do you currently, or did you previously live
together with a daily smoker after your
20th birthday? 
8.4 Do you/did you smoke daily? ..................
If NEVER: Go to question 9 : (EDUCATION AND WORK)
8.5 If you smoke daily now, do you smoke:
8.6 If you previously smoked daily, how
long is it since you quit? Number of years











Cod liver oil, fish oil capsules ..............
Vitamins and/or mineral supplements?
7.4 How much of  the following do you usually drink?
(Tick once per line)
7.5 Do you usually drink soft drink: with sugar 1 without sugar      2
7.6 How many cups of coffee and tea do you drink daily?
(Put 0 for the types you don't drink daily)
7.7 Approximately how often have you during the last year 
consumed alcohol? (Do not count low-alcohol and alcohol-free beer)
7.8 When you drink alcohol, how many
glasses or drinks do you normally drink? number
7.9 Approximately how many times during the last
year have you consumed alcohol equivalent to




















Yes, daily Sometimes No
1               2             3              4              5             6
Full milk, full-fat curdled milk, 
yoghurt ..................................
Semi-skimmed milk, semi-skimmed 
curdled milk,low-fat yoghurt ......
Skimmed milk, skimmed 
curdled milk ..............................
Extra semi-skimmed milk ......
Juice .....................................
Water ....................................
Mineral water (e.g. Farris, 
Ramløsa etc)
Cola-containing soft drink .....














1 2            3            4            5
Filtered coffee ..........................................................
Boiled coffee/coarsely ground coffee for brewing .....



















1              2        3 4
5               6        7 8
7.10 When you drink, do you normally drink:(Tick one or more)
Beer Wine Spirits 
9.1 How many years of education
have you completed? Number of years
(Include all the years you have attended school or studied)
9.2 Do you currently have paid work?
9.3 Describe the activity at the workplace  where 
you had paid work for the longest period in the
last 12 months. (e.g. Accountancy firm, school, paediatric  
department, carpentry workshop, garage, bank, 
grocery store, etc.)
Business:
If retired, enter the former business and occupation.
Also applies to 9.4
9.4 Which occupation/title have or had you at this workplace?
(e.g. Secretary, teacher, industrial worker, nurse,
carpenter, manager, salesman, driver, etc.)
Occupation:
9.5 In your main occupation, do you work as self-employed, 
as an employee or family member without regular salary?
9.6 Do you believe that you are in danger of losing 
your current work or income within the next 
two years? ...........................................................
9.7 Do you receive any of the following benefits?
Yes No





Sickness benefit (are on sick leave) .......................
Old age pension, early retirement (AFP) or
survivor pension ..................................................... 
Rehabilitation/reintegration benefit .........................
Disability pension (full or partial) .............................
Unemployment benefits during unemployment .......
Social welfare benefits ............................................
Transition benefit for single parents ........................
How many cigarettes do you or did you
normally smoke per day? Number of cigarettes
How old were you when you began
daily smoking? Age in years
How many years in all have you
smoked daily? Number of years
Yes       No
Yes No
Yes, full-time Yes, part-time No1                    2                  3




(not sweating/out of breath)...
Hard physical activity
(sweating/out of breath).........
Blood pressure lowering drugs ...................
Cholesterol-lowering drugs .........................
Reading, watching TV or 
other sedentary activity? ......................................... .........
Walking, cycling or other forms of  
exercise at least 4 hours a week? .....................................
(Include walking or cycling
to work, Sunday walk/stroll,etc.)
Participation in recreational sports, heavy gardening, etc.?
(Note: duration of activity at least 4 hours a week)
Participation in hard training or sports competitions, 
regularly several times a week? ........................................
None Less than 1 1-2 3 or more
10.1 How has your physical activity in leisure time been 
during this last year?
Think of a weekly average for the year.
Time spent going to work is count as leisure time. Answer both questions.
11.3 How much interest do people show for what you do?
(Tick only once)
11.4 How many associations, sport clubs,groups, religious
        communities or similar do you take part in?  Number
(Write 0 if none)
11.5 Do you feel that you can influence what happening
in your local community where you live? (Tick only once)
12.1 Have one or more of your parents or siblings
had a heart attack (heart wound) or
angina pectoris (heart cramp)? ..........................
12.2 Tick for the relatives who have or have
had any of the illnesses: (Tick for each line)
Cerebral stroke or 
brain haemorrhage .......
Heart attack




12.3 If any relatives have diabetes, at what age did they get
diabetes (if for e.g. many siblings, consider the one who 
got it earliest in life):
11.2 How many good friends do you have? Number of friends
Count the ones you can talk confidentially with
and who can give you help when you need it.
Do not count people you live with, but do include
other relatives.
10.2 Describe exercise and physical exertion in your leisure time.
If your activity varies much e.g. between summer and winter, 
then give an average. The question refers only to the last year.
(Tick the most appropriate box)
1 2 3                 4
10. EXERCISE AND PHYSICAL ACTIVITY
11. FAMILY AND FRIENDS
12. ILLNESS IN THE FAMILY
13. USE OF MEDICINES
14. THE REST OF THE FORM IS TO
BE ANSWERED BY WOMEN ONLY
13.1 Do you use:
14.1 How old were you when you  
started menstruating? Age in years
14.2 If you no longer menstruating, how old were
you when you stopped menstruating? Age in years
14.3 Are you pregnant at the moment?
14.4 How many children have you 
        given birth to? Number of children
14.5 Do you use, or have you ever used?
(Tick once for each line)
13.2 How often have you during the last 4 weeks used
the following medicines?
(Tick once for each line)
13.3 For those medicines you have checked in points 13.1 and 























Mother's age Father's age Brother's age Sister's age Child's age
Father Brother Sister Child
None
of these
Yes, some Yes, a little No
Never 
tried




With medicines, we mean drugs purchased at pharmacies.
Supplements and vitamins are not considered here.
Painkillers non-prescription ....




Other prescription medicines ...
Oral contraceptive pills/mini pill/
contraceptive injection ................
Hormonal intrauterine device (IUD)
(not ordinary IUD)..
Estrogen (tablets or patches) .....
Estrogen (cream or suppositories)
State the name and the reason that you are taking/have taken
these (disease or symptom):











Name of the medicine: Reason for use of Up to 1 year
(one name per line) the medicine 1 year or more
If there is not enough space here, you may continue on a separate sheet that you attach
How long have you
used the medicine
Yes No Uncertain Above fertileage 






























but not now Never
14.6 If you use/have used prescription estrogen:
How long have you used it? Number of years
14.7 If you use contraceptive pills, mini pill, contraceptive 
injection, hormonal IUD or estrogen, what brand do you use?
1 2 3 4
1          2                    3        4                 5
11.1 Do you live with:
Spouse/partner?.........................................
NoYes
Appendix 3: Questionnaire 2
E
Do not write here:









Fibromyalgia/chronic pain syndrome .....
Psychological problems for which you 
have sought help ....................................
A heart attack .........................................
Angina pectoris (heart cramp) ................
Cerebral stroke/brain haemorrhage ........
Have one or more of your parents or siblings had:
NoYes
What is your current state of health? (Tick only once)
Poor Not so good Good Very good
1                  2               3           4
Do you get pain or discomfort in the chest when:
Walking up hills, stairs, or walking fast on level ground?
If you stop, does the pain disappear 
within 10 minutes? .............................................
Can such pain occur even if you are at rest?....
If you get such pain, do you usually:
Stop? Slow down? Carry on at the same pace?






A heart attack (heart wounds) or




E1. YOUR OWN HEALTH E3. COMPLAINTS
E4. TEETH, MUSCLE AND SKELETON
E5. EXERCISE AND PHYSICAL ACTIVITY
E6. BODY WEIGHT
E2. ILLNESS IN THE FAMILY
Below is a list of various problems.
Have you experienced any of this during the last week
(including today)?
(Tick once for each line)
Sudden fear without reason ..........
Felt afraid or anxious ....................
Faintness or dizziness ..................
Felt tense or upset ........................
Tend to blame yourself ..................
Sleeping problems.........................
Depressed, sad .............................
Feeling of being useless, worthless ..
Feeling that everything is a struggle










  1 2 3 4
How many teeth have you lost/extracted? Number of teeth
(disregard milk-teeth and wisdom teeth)
Estimate your body weight when you 
were 25 years old: kg.
Have you been bothered by pain and/or stiffness in 
muscles and joints during the last 4 weeks?
Neck / shoulders ....................
Arms, hands..........................
Upper part of the back ..........
Lumbar regions ....................








Have you ever had:
Fracture in wrist/forearm? ........................
Hip fracture?............................................
Have you fallen down during the last year? (Tick once only)
NoYes




(not sweating/out of breath).....
Hard physical activity
(sweating/out of breath)............
Less than 1None 1-2 3 or more
How has your physical activity been during this last year?
Think of a weekly average for the year.
Answer both questions.
1                   2 3                 4
Hours per week
1              2                 3
Tick for the relatives who have or have
had any of the illnesses: (Tick for each line)
Cerebral stroke or 
brain haemorrhage ...
Heart attack




If any relatives have diabetes, at what age did they get 
diabetes (if for e.g. many siblings, consider the one who 

















Fat fish (e.g. salmon, 
trout, mackerel, herring)
E7. EDUCATION
E8. FOOD AND BEVERAGES
E9. SMOKING
E10. BODILY FUNCTIONS AND SAFETY
How often do you usually eat these foods?
(Tick once for each line)
Do you use dietary supplements:
How many hours a day do you normally spend
in smoke-filled rooms? Number of total hours
Did any of the adults smoke at home
while you were growing up? ........................... 
Do you currently, or did you previously live
together with a daily smoker after your 20th 
birthday?
Do you/did you smoke daily? .................
If you have NEVER smoked daily;
Go to question E11  (BODILY FUNCTIONS AND SAFETY)
If you smoke daily now, do you smoke:
If you previously smoked daily, how
long is it since you quit? Number of years
If you currently smoke, or have smoked 
previously:
Cod liver oil, fish oil capsules ................
Vitamins and/or mineral supplements ...
How much of the following do you usually drink?













1               2                 3                 4                 5                 6
Yes, daily Sometimes No
Full milk, full-fat curdled 
milk, yoghurt ...........................
Semi-skimmed milk, semi-skimmed 
curdled milk, low-fat yoghurt .......
Skimmed milk, skimmed 
curdled milk .........................
Extra semi-skimmed milk ....
Juice ...................................
Water ..................................














1 2 3                4                 5
123
1                   2      3      4
How many years of education have 
you completed? Number of years
(include all the years you have attended school or studied)
Would you feel safe by walking alone in the evening
in the area where you live?
When it comes to mobility, sight and hearing, can you:
(Tick once for each line)
Do you because of chronic health problems have
difficulties with: (Tick once for each line)
Take a 5 minute walk
in fairly high pace? ................
Read ordinary text in newspaper,
if necessary with glasses? .........
Hear what is said in a
normal conversation? ............
Move around in your home? .................
Get out of your home by yourself? .......
Participate in organization or other 
leisure time activities? ..........................
Use public transport? ............................












How many cigarettes do you or did you 
normally smoke per day? Number of cigarettes
How old were you when you began 
daily smoking? Age in years
How many years in all have 
you smoked daily? Number of years














Approximately, how often have you during the last year  
consumed alcohol? (Do not count low-alcohol and alcohol-free beer)
When you drink alcohol, how many 
glasses or drinks do you normally drink? Number
Approximately how many times during the last 
year have you consumed alcohol equivalent to
5 glasses or drinks within 24 hours? Number of times
Filtered coffee ...........................................................
Boiled coffee/coarsely ground coffee for brewing .....



















1              2        3 4
5               6         7 8
Number of cups
How many cups of coffee and tea do you drink daily?
(Put 0 for the types you do not drink daily)
Name of the medicine: Reason for use of Up to One year
(one name per line): the medicine: 1 year or more
Blood pressure lowering drugs .............
Cholesterol-lowering drugs ...................
Drugs for osteoporosis ..........................
Insulin.....................................................
Tablets for diabetes ................................
How much interest do people show for what you do?
(Tick only once)
How many associations, sport clubs, 
groups, religious communities, 
or similar do you take part in? Number 
(write 0 if none)
Do you live: At home? In an institution/shared apartment?
Do you live with:
Spouse/ partner?.......................
Other people? ...........................
How many good friends do you have?
Count the ones you can talk confidentially with
and who can give you help when you need it.
Do not count people you live with, but do include
your children and other relatives........................
How many times in the last 12 months
have you been to/used:
(Tick once for each line)
Are you confident that you 
will receive health care and 
home assistance if you need it?
E11. USE OF HEALTH SERVICES
E12. FAMILY AND FRIENDS
E13. CHILDHOOD/YOUTH AND AFFILIATION
E14. USE OF MEDICINES
E15. THE REST OF THE FORM IS TO
BE ANSWERED BY WOMEN ONLY
Do you use?
(Tick once for each line)
How old were you when you  
started menstruating? Age in years
How old were you when you 
stopped menstruating? Age in years




Do you use, or have you ever used estrogen?
How often have you during the last 4 weeks used the 
following medicines?














1      2          3               4                   5
With medicines, we mean drugs purchased at pharmacies. 
Supplements and vitamins are not considered here
Painkillers non-prescription........ 




Other prescription medicines ....
Tablets or patches .....................
Cream or suppositories .............










If there is not enough space here, you may continue on a separate sheet that you attach.
How long have you
used the medicine
Never Previously Now
If you use estrogen, which brand you use now?
Have you ever used contraceptives pills? ......
1 2 3 4
A general practitioner (GP) ..............
Specialist (private or out-patient clinic)
Emergency GP (private or public).....
Hospital admission ...........................
Home nursing care ..........................
Physiotherapist ................................
Chiropractor .....................................







How long altogether have you lived  in the county?
How long altogether have you lived in 
the municipality?
Where did you live most of the time before the age of 16?
(Tick one option and specify)
Same municipality.........
Another municipality
in the county.................. Which one:
Another county in Norway Which one:
Outside Norway ........... Country:
Have you moved during the last five years?
No Yes, once Yes, more than once










































State the name of the medicines you are using now and the 
reason you are taking the medicines (disease or symptom):




1.1 In which municipality did you live at the age of 1 year?
(If you have not lived in Norway, state country of residence
instead of the municipality)







T1. NEIGHBORHOOD AND HOME
Additional questions to the health survey
in Troms and Finnmark 2001-2002
The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The study is also intended to improve our 
knowledge of cancer and other general conditions, such 
as allergies, muscle pains and mental conditions. We 
would therefore like you to answer some questions about 
factors that may be relevant for your risk of getting these 
and other illnesses. This form is part of the Health Survey, 
which has been approved by the Norwegian Data 
Inspectorate and the Regional Board of Research Ethics. 
The answers will only be used for research purposes and 
will be treated strictly confidential. 
The information you give us may later be linked with
information from other public health registers in accordance
with the rules laid down by the Data Inspectorate and the
Regional Board of Research Ethics.
If you are unsure about what to answer, tick the box that 
you feel fits best.
The completed form should be sent to us in the enclosed 
prepaid envelope. Thank you in advance for helping us.
Yours sincerely
National Health 
Screening ServiceUniversity of Tromsø
If you do not wish to answer the questionnaire, tick the box 
below and return the form. Then you will not receive reminders.
I do not wish to answer the questionnaire
T1. NEIGHBORHOOD AND HOME (cont.)







1.8 How often do you normally take part in organised
gatherings, e.g. sewing circles, sports clubs,  
political meetings or other associations?
(Tick only once)
Never, or just a few times a year .....................
1-3 times a month ............................................
Approximately once a week .............................
More than once a week ....................................
Mostly sedentary work?
(e.g. office work, mounting) ..............................
Work that requires a lot of walking?
(e.g. shop assistant, light industrial work, teaching)
Work that requires a lot of walking and lifting?
(e.g. Postman, nursing, construction) ...............
Heavy manual labour?










1.3 How big is your house? m2 (gross)
Yes
1.4 Are you bothered by: (Tick once for each line)
Moisture, drought or coldness in your home 
Other forms of bad indoor climate  ..........
Traffic noise (cars or aircraft) ...................
Other noise (industrial, construction, etc.) .....
Neighbour noise .......................................
Drinking water quality ...............................
Air pollution from traffic ............................








Yes   No
1.6 What do you consider yourself as?
(Tick for one or more alternatives)
2.1 If you have paid or unpaid work, how would you
describe your work? (Tick only once)
No, not at all ....................................................
To a small extent .............................................
Yes, to a large extent .......................................





2.2 Can you decide yourself how your work (paid
or unpaid) should be organised? (Tick only once)
2.3 Are you on call, do you work 
shifts or nights?









1.5 What home language did your grandparents have?
(Tick for one or more alternatives)







T5. FOOD AND DIETARY SUPPLEMENTS
T6. BODY WEIGHT
T7. ILLNESSES AND INJURIES
3.1 Do you smoke?
If “Yes, sometimes”,
What do you smoke?
If YES:
How many years altogether have you
used snuff?
4.5 Have you, in one or more periods in the last 
5 years consumed so much alcohol that it has
inhibited your work or social life?
5.4 Do you use the following dietary supplements?
7.1 Have you ever had:
Tick once for each question. Also give the age 
at the time. If you have had the condition 
several times, how old were you the last time
Iron tablets .....................................
Calcium tablets or bonemeal .........
Vitamin D supplements ..................



















Atopic eczema (e.g. childhood eczema)
Hand eczema........................................
Food allergy .........................................





Peptic ulcer surgery ......................
Neck surgery .................................
Prostate surgery ............................










1          2    3                  4
6.1 Do you currently try to change your
body weight?
No
Yes, I try to
gain weight
Yes, I try to 
lose weight
1            2    3
No 1-2 times More than 2 times
1          2   3
1                 2         3














7.2 Do you have, or have you ever had:
(Tick once for each question)
Yes, daily
Cigarettes Pipe Cigar/cigarillos
Yes, sometimes No, never
5.3 How important is it for you to have a healthy diet?
1   2                  3          4
Very Somewhat Little Not
3.2 Have you used or do you use snuff daily?
Yes, now Yes, previously Never
Yes   No
4.1 Are you a teetotaller?..................................
Yes   No
5.1 Do you usually eat breakfast every day?...
7.3 Have you had common cold, influenza,
gastroenteritis, etc. during the last 14 days?
7.4 Have you during the last 3 weeks had
common cold, influenza, bronchitis, 
pneumonia, sinusitis, or other respiratory
infection?......................................................
7.5 Have you ever had bronchitis or 
pneumonia?..................................................
7.6 Have you during the last 2 years had 
bronchitis or pneumonia? (Tick only once)
4.2 How many times a month do you
normally drink alcohol?..................
(Do not count low-alcohol beer.
Put 0 if less than once a month)
4.3 How many glasses of beer, wine or spirits
do you normally drink in a fortnight?
(Do not count low-alcohol beer.
Put 0 if you do not drink alcohol)
Number of times
years
4.4 For approximately how many years
has your alcohol consumption been at 
the same level you described above? years
5.2 How many times a week do you
eat a warm dinner?.......................................
6.2 What weight would you be satisfied .....




T8. SYMPTOMS T8. SYMPTOMS (continue)
T9. MEDICINES
8.2 Do you cough about daily for periods of the year?
If YES:
8.11 Do you usually sleep during the day?...........
8.12 How often do you suffer from urinary incontinence?
Never ................................................................
Not more than once a month ............................
Two or more times a month ..............................
Once a week or more .......................................
8.1 Have you in the last two weeks felt:
(Tick once for each question)
8.5 Do you get short-winded in the following situations?
(Tick once for each question)
While walking fast on level ground
or slight up hills .....................................................
While walking calmly on 
level ground ..........................................................
While washing or dressing yourself ......................
While resting .........................................................
8.6 Do you have to stop because of short-windedness
while walking in your own pace on level ground?...
Is your cough productive? ................................
Have you had this kind of cough for as long 
as 3 months in each of the last two years?......





Yes   No
8.4 Do you get pain in the calf while walking ..........
If YES:
How long can you go
before you notice the pain?...............
8.13 Are you able to walk down 10 steps without 
holding on to something (e.g. a handrail) ....
8.14 Do you use glasses?.......................................
8.15 Do you use a hearing aid?..............................
8.16 How is your memory?
(Tick once for each question)
Do you forget what you just have
heard or read?.....................................................
Do you forget where you have placed things?.....
Is it more difficult to remember now than earlier?..
Do you more often write memos now than earlier?
If “YES” on one of these questions;
Is this a problem in your daily life?................
Drugs for
osteoporosis....................
Tablets for diabetes ........
Drugs for hypothyroidism
(thyroxine) ......................
Yes   No
Yes   No
Yes   No
8.7 Have you during the last year suffered from
pain and/or stiffness in muscles and joints
that have lasted continuously for 
at least 3 months?...............................................
If YES:
Has the complaint reduced your leisure 
time activity? .......................................................
For how long has the complaint endured in total?
Yes   No
Yes   No
Yes   No




Has the complaint reduced your ability to work during 
the last year? (Also applies to domestic workers and 
pensioners (Tick once)
Have you been on sick leave due to these
complaints during the last year?................
No/insignificantly To some extend Significantly reduced Do not know
1               2        3  4
Yes   No
Do not
work
9.1 Do you use, or have you used any of
the following medicines:
9.2 Do you use any medicines which you take 
as injections? ...................................................
If YES:
Give the name of the medicines (for injection):





used 1st time Never
used
meter
8.8 How often do you suffer from sleeplessness?
(Tick only once)
Never, or just a few times a year .......................
1-3 times a month ..............................................
Approximately once a week ..............................









8.9 If you suffer from sleeplessness monthly or more
frequently, what time of the year does it affect you most?
No particular time of the year ............................
Especially during the polar night ........................
Especially during the midnight sun season ........
Especially in spring and autumn .........................
8.10 Have you in the last year suffered from 
sleeplessness to the extend that it has 
affected your ability to work ? ........................
Yes   No
Yes   No
Yes   No
Yes   No




Nervous or worried .....................
Bothered by anxiety.....................
Confident and calm ....................
Irritable.........................................
Happy and optimistic ..................
Down/depressed ........................
Lonely..........................................
8.3 Have you had episodes with wheezing in the chest?
If YES:
Has this occurred: (Tick once for each question)
At night ..................................................................
In connection with respiratory infections ...............
In connection with physical exertion ......................
In connection with very cold weather .....................
T10. ILLNESS IN THE FAMILY
T11. MOBILE TELEPHONE



























12.2 If you still have mensturate or are pregnant:
What date did your last menstruation start?
12.5 Do you use or have you used oral 
        contraceptive pills?..............................
If YES:
How old were you when 
you started taking the pill?..................
How many years in total
have you taken the pills?.... Number of years
If you have given birth:
How many years did you take the pill 
before your first delivery?...  Number of years
If you stopped taking the pill:
How old were you when you stopped?....
12.6 Apart from pregnancy and after giving
birth, have you ever stopped having
menstruation for 6 months or more?.
If YES:
How many times?........................
12.7 How is your current menstruation status?
I have not had menstruation in the last year
I have regular menstruation ........................
I have irregular menstruation ......................
12.8 When you were 25-29 years old, how many days
usually passed between the start of two periods?
The periods were of approximately
equal length every time?...............
How many days did a typical
menstrual bleeding period last?...
Thank you for the help!
Remember to mail the form today!
(If more children, use additional sheet)
12.4 Do you use or have you used prescribed
estrogen (tablets or patches)?..................
If YES:
How old were you when 
you started taking estrogen ? .............
If you stopped using estrogen,
How old were you when 






10.1 Tick for the relatives who have or have ever had
any of the diseases: (Tick for each line)
10.2 How many siblings and children do you have?
10.3 Do you usually do extra caring work because
of illness etc. in your close family?
Heart attack (heart wound)
Angina pectoris (heart cramp)
High blood pressure ........
Aneurysm.........................













Yes, daily/almost daily Yes, sometimes No
1                2        3
11.1 Do you have (own, rent, etc.) a mobile telephone?
If Yes:
What do you use your mobile telephone for, and how 
often do you use it?(Tick once for each line)
T12. THE REST IS TO BE ANSWERED BY WOMEN ONLY
12.1 If you have given birth, fill in each child's birth year and 
how many months you breastfed after delivery.
(If you did not breastfeed, write 0)
Number of months







Yes, always Yes, sometimes
30 or
more
10-29 2-9 1 or
less
Never
Number of times per day
No
1                2         3
12345
Yes   No10.4 Do you/your family receive home aid 
or home nursing care?.................................
10.5 Is your mother alive? .......






12.3 If you no longer menstruate; why did
your periods stop? (Tick once)
It stopped by itself ............................................
Uterus surgery .................................................
Surgically removed both ovaries ......................







































30-34 654 348 53.2 628 237 37.7 
35-39 87 75 86.2 55 46 83.6 
40-44 559 389 69.6 533 315 59.1 
45-49 520 373 71.7 473 299 63.2 
50-54 96 92 95.8 160 144 90.0 
55-59 674 630 93.5 232 219 94.4 
60-64 916 827 90.3 744 657 88.3 
65-69 687 636 92.6 637 591 92.8 
70-74 683 604 88.4 542 495 91.3 
75-79 627 495 78.9 470 390 83.0 
80-84 202 145 71.8 156 114 73.1 
+85 12 5 62.5 6 4 66.7 
Total 5717 4619 80.8 4636 3511 75.7 
 











Appendix 6: Data transformation 











































          
 
 
 
 
 
 
